tiprankstipranks
Trending News
More News >

Denali Therapeutics price target lowered to $29 from $30 at Baird

Baird lowered the firm’s price target on Denali Therapeutics (DNLI) to $29 from $30 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the Tivi BLA was submitted and the commercial launch is on track for early 2026.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue